Alector Inc (NASDAQ:ALEC) VP Calvin Yu sold 1,315 shares of Alector stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $19.39, for a total value of $25,497.85.
Shares of Alector stock traded down $0.23 during trading on Thursday, hitting $19.39. 269,415 shares of the stock were exchanged, compared to its average volume of 298,075. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.57 and a quick ratio of 6.56. The firm’s 50-day moving average price is $16.65 and its 200 day moving average price is $17.54. The stock has a market cap of $1.28 billion and a price-to-earnings ratio of -4.20. Alector Inc has a 12-month low of $13.64 and a 12-month high of $27.00.
Alector (NASDAQ:ALEC) last posted its earnings results on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.07). Alector had a negative net margin of 378.57% and a negative return on equity of 58.27%. The business had revenue of $2.70 million during the quarter. As a group, research analysts forecast that Alector Inc will post -1.63 earnings per share for the current year.
Several equities research analysts have weighed in on the company. Cowen restated a “buy” rating on shares of Alector in a report on Tuesday, November 12th. BTIG Research initiated coverage on Alector in a research report on Wednesday, November 27th. They issued a “buy” rating and a $28.00 price target on the stock. ValuEngine cut Alector from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Zacks Investment Research raised Alector from a “sell” rating to a “hold” rating in a research report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $27.00.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Metropolitan Life Insurance Co NY acquired a new position in shares of Alector during the 3rd quarter worth about $150,000. Millennium Management LLC raised its position in shares of Alector by 124.1% during the 3rd quarter. Millennium Management LLC now owns 321,671 shares of the company’s stock worth $4,638,000 after acquiring an additional 178,111 shares in the last quarter. Barclays PLC lifted its stake in Alector by 80.7% during the third quarter. Barclays PLC now owns 25,597 shares of the company’s stock worth $369,000 after purchasing an additional 11,431 shares during the last quarter. California State Teachers Retirement System lifted its stake in Alector by 212.0% during the third quarter. California State Teachers Retirement System now owns 47,206 shares of the company’s stock worth $681,000 after purchasing an additional 32,076 shares during the last quarter. Finally, Mascoma Wealth Management LLC acquired a new position in Alector in the third quarter valued at approximately $2,681,000. 49.75% of the stock is owned by institutional investors.
Alector Company Profile
Alector, Inc, a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease.
See Also: Insider Trading – What You Need to Know
Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.